The genetic mechanisms underlying hypertension are unclear, but relative aldosterone excess, present in Ϸ10% of hypertensive patients, is known to be a heritable trait. This phenotype associates with a T/C single nucleotide polymorphism (SNP) at position -344 of the aldosterone synthase gene (CYP11B2). However, deletion of this SNP has no effect on gene transcription. We have identified another T/C SNP at -1651, in tight linkage disequilibrium with the -344 SNP and here investigate its functional effect on CYP11B2 transcription.
H ypertension is the leading modifiable risk factor for cardiovascular disease, 1 but its etiology remains unclear. Blood pressure is a heritable trait, yet despite extensive genome-wide association studies involving thousands of subjects and examining millions of SNPs, 2,3 only a small proportion of blood pressure heritability can be accounted for. The relatively few key modifier genes that such studies have managed to identify may be explained, in part, by their lack of detailed subphenotyping. In this regard, approximately 10% of hypertensive subjects have an elevated aldosteroneto-renin ratio (ARR), 4 and it is likely that mechanisms governing the regulation of aldosterone play an important part in the development of hypertension in these subjects. The high heritability of both aldosterone 5 and the ARR 6 are consistent with their genetic regulation. A C/T single nucleotide polymorphism (SNP) in the promoter region of the aldosterone synthase gene (CYP11B2), at position -344 (rs1799998), has previously been associated with hypertension 7-10 and with elevated aldosterone levels in urine and plasma. 10 -12 Although this locus was not identified in GWA studies of hypertension, the size and scale of these investigations preclude detailed subphenotyping, including accurate indices of aldosterone production.
More focused investigations showed association between variation at CYP11B2, blood pressure, and indices of aldosterone production, 7,8,10 -12 while a comprehensive meta-analysis 9 found an association with hypertension and elevated ARR. However, deletion of the -344 C/T site does not significantly affect promoter activity in vitro. 13 The locus encompassing CYP11B2 is one of high linkage disequilibrium (LD); therefore, it seems plausible that the true causal variant underlying this hypertensive effect is in LD with the -344 SNP, which is acting as a marker. We demonstrate here that a candidate CYP11B2 C/T SNP at position -1651 (rs13268025) is in strong LD with the -344 SNP, and that allelic variation at -1651 associates with reduced transcriptional activity in vitro. The -1651 SNP is encompassed by a binding site for the multifunctional protein DNA (apurinic or apyrimidinic site) lyase, also called APEX 1 (or, variously, APE1, HAP1, or REF1). Here, we provide evidence for its differential binding to the contrasting -1651 alleles and demonstrate its action as a transcriptional repressor of CYP11B2. Finally, we show that the -1651 alleles associate with altered excretion of urinary aldosterone metabolites in man.
Methods

Reporter Gene Assays
H295R cells were grown in DMEM/F12 medium supplemented with 2% Ultroser G serum (Pall Scientific, Saint-Germain-en-Laye, France), 1% ITS, and 1% penicillin/streptomycin at 37°C, 5% CO 2 , and transfected with pGL3-derived expression vectors (Firefly luciferase) (Promega, Fitchburg, WI) using siPORT™ NeoFX™ Transfection Agent (Applied Biosystems, Foster City, CA) according to the manufacturer's protocol. Vectors contained 1.8kb of CYP11B2 promoter and were identical apart from the inclusion of a C or T at the -1651 position (the latter generated by site-directed mutagenesis). The pGL4.73 (renilla luciferase) (Promega) was cotransfected to control for transfection efficiency. After 24 hours, transfectant was removed and replaced with normal media, with media containing angiotensin II or the APEX1 inhibitor E3330 for 24 hours (each with nϭ6). For APEX1 overexpression studies, cells were transfected with the CYP11B2 reporter constructs in addition to APEX1 cDNA expression vector (OriGene, SC119121) or control vector (OriGene, pCMV6-XL5) (each nϭ4), and stimulated with angiotensin II (1ϫ10 Ϫ7 M). For siRNA experiments, cells were transfected with siRNA targeted to APEX1/Ref1 (human ref1, sc-29470, Santa Cruz, CA) or with a scrambled control siRNA (control A, sc-37007, Santa Cruz). Each experiment was repeated in triplicate. Data are presented as mean and standard error of mean (SEM) and analyzed with Student t test.
Electrophoretic Mobility Shift Assay
Nuclear protein extract preparation was modified from Dignam et al, 14 and details are given in the Online Supplement. Nuclear protein was added to a 32 P-labeled double-stranded DNA probe encompassing the -1651 site with binding buffer (see Online Supplement). After 30-minute incubation at room temperature, samples were analyzed by fractionation on a nondenaturing 6% (wt/vol) polyacrylamide gel followed by autoradiography. The electrophoretic mobility shift assay (EMSA) was repeated 3 times, twice with protein aliquots from the same nuclear extraction and a third time with a second, independently extracted protein sample.
Biotinylated Oligonucleotide Pull-Down Assay
Nuclear protein from confluent H295R cells was obtained as detailed in the Online Supplement. We incubated 400 g nuclear protein at room temperature with buffer as described before further incubation with double-stranded biotinylated oligonucleotide either encompassing the -1651 SNP site or containing scrambled sequence. Resulting protein-DNA complexes were captured by incubation with neutravidin-conjugated agarose.
Tandem Mass Spectroscopy
SNP-binding proteins were purified, as above. Samples were separated by SDS PAGE (4%-15% gradient gel) and stained with colloidal coomassie blue. Gels were destained and protein bands then excised and sent to the Fingerprints Proteomics Facility, University of Dundee (Dundee, UK). Samples were processed by trypsin digestion and peptides identified from their mass footprint using MASCOT.
Western Blotting
Proteins captured during the biotinylated oligonucleotide pull-down assay were eluted from the beads by a 30-minute, 37°C incubation in 50 L Laemmli buffer. Samples were then fractionated by SDS-PAGE, transferred, and probed with APEX1 antibody (Abgene, UK), as described in the Online Supplement. We ran 10% of the original extract alongside the pull-down samples as both a positive control and an indicator of relative binding of APEX 1 to our oligos.
Chromatin Immunoprecipitation Assays
Chromatin immunoprecipitation assays (ChIP) assays were performed using modifications of previous methods 15, 16 and are described in full in the Online Supplement. Briefly, chromatin was harvested from confluent H259R cells fixed in 1% formaldehyde. Chromatin was sheared to fragments of Ϸ500 base pair (bp) genomic DNA. Samples were precleared using protein G sepharose (Sigma, St. Louis, MO), and then subjected to overnight immunoprecipitation at 4°C with APEX1 antibody (Novus Biologicals, Littleton, CO) or nonimmune control serum. Following washing and reversal of cross-links, we analyzed samples by CYP11B2 promoter-specific RT-PCR, which amplified a 128 bp fragment spanning the -1651 SNP site, using an ABI 7900 HT Prism Sequence Detection System (Applied Biosystems).
Human Genetic Analysis and Steroid Phenotype
Ethical approval was granted by the West Glasgow Ethics Committee, and written informed consent was obtained from all participants; investigations were carried out in accordance with the principles of the Declaration of Helsinki. Calculations showed that 60 volunteers would achieve 0.80 power to detect a difference of 20% in urinary tetrahydroaldosterone (THAldo) excretion rate, with ␣ of 0.05. Sixty volunteers, in good health, ages 18 to 70 years and not on any antihypertensive or steroid-containing medication, were recruited from the local community. Subjects were instructed to adhere to a standard salt diet for 4 days; written instructions were issued (included in Online Supplement) and reinforced by the investigator (F.M.). We collected 24-hour urine samples on the final day. The volume was measured before being aliquoted; adherence to standardized salt intake was assessed by measurement of 24-hour urinary sodium excretion. Steroid metabolites were measured by gas chromatography, after the method of Shackleton. 17 The 2kb promoter region of CYP11B2 was amplified by PCR and sequencing undertaken in 3 separate reactions to establish genotype at sites of polymorphic variation as well as the -344 SNP. These sites of polymorphic variation are -470 (rs10087214), -645 (rs11781082), -663 (rs28659182), -1472 (rs62524560), -1513 (rs62524561), -1651 (rs13268025), and -1667 (rs13254375). These sites have previously been suggested to be in linkage disequilibrium with the polymorphism at -344. 18 This analysis was performed in all 60 normal volunteers. Primers and sequencing conditions are included in the Online Supplement.
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Results
Pattern of Linkage Disequilibrium Across the CYP11B2 Promoter
Previous investigations have demonstrated a high degree of LD across the CYP11B2 locus; 7 polymorphisms up to 2 kilobases upstream of the transcriptional start site have been previously identified as being in LD with the -344 SNP. 18 As detailed LD data for this region are not currently available on public access databases (http://hapmap.ncbi.nlm.nih.gov/, http://www.ensembl.org/index.html), we confirmed the precise pattern of LD across the locus in a group of 60 normotensive volunteers recruited from the local area (Glasgow, UK). DNA was extracted and sequenced across the CYP11B2 promoter, identifying the LD pattern for these SNPs. Allele frequencies were calculated and their distribution found to be consistent with random distribution, according to Hardy-Weinberg equilibrium ( Table 1 ). The degree of LD was high, with a DЈ value consistently Ͼ0.95 across the region (Online Figure I ). Bioinformatic screening (using TRANSFAC) indicated changes in putative transcription factor-binding sites that could result from polymorphisms in the region. While all such SNPs were shown to potentially alter DNA-protein interaction, the polymorphism at -1651 was suggested to influence binding of transcription factors implicated in the regulation of steroidogenesis, including NR5A1 (steroidogenic factor 1, SF-1). Thus, the -1651 SNP was selected for further study.
Effect of the -1651 SNP on CYP11B2 Transcription and Protein: DNA Binding
Reporter gene assays were undertaken to assess the effect of polymorphic variation at -1651. Two plasmids were constructed, each containing 1880 bp of the CYP11B2 promoter fused to a luciferase reporter gene. These plasmids were identical except for a single base change at position -1651 (T/C). The plasmids were transfected separately into H295R, a human adrenocortical carcinoma cell line. Under basal conditions, the -1651C plasmid was found to have greater transcriptional activity than the -1651T plasmid ( Figure 1A ). As expected, incubation of H295R cells with angiotensin II (1ϫ10 Ϫ7 M), the principal trophin of aldosterone, stimulated the transcription of both constructs, but the raised level of -1651C transcription over -1651T was even more pronounced ( Figure 1B) .
In order to assess whether the polymorphic variation at this site could alter DNA-protein interactions, an electromobility shift assay (EMSA) was undertaken using H295R nuclear extracts together with -1651C or -1651T oligonucleotide probes. Nuclear proteins were prepared using buffers with varying sodium chloride conditions (as this can affect DNAprotein binding). Clear differences in DNA-protein binding were seen in the presence of the T allele or the C allele ( Figure 1C ) and, while the pattern of oligonucleotide-protein binding changed when the properties of the extraction buffer was altered, particularly with reference to the higher molecular weight band, the complexes of lower molecular weight showed the same allele-dependent difference under all extraction conditions. This confirmed that the presence of the T or C variant had the potential to alter nuclear protein binding at this site.
Rather than use the EMSA to identify proteins differentially bound to each allele by attempting to "supershift" complexes with antibody to a nominated protein, H295R nuclear extracts were incubated with 5Ј-biotinylated double-stranded DNA probes and streptavidin-agarose beads. The resulting protein-DNA complexes were separated by SDS-PAGE. Two discrete bands were identified in the presence of the T allele and not in the C allele. Following trypsin digestion, the peptide fragments were analyzed by tandem mass spectrometry (FingerPrints Proteomics Facility College of Life Sciences, University of Dundee). Fragments corresponding to the peptide sequence of the transcription factor hnRNPK were identified in one of the protein-DNA complexes. This transcription factor was not investigated further in this work. In the other protein-DNA complex, APEX1 was identified. A biotinylated pull-down assay using an antibody specific to APEX1 confirmed APEX1 binding to oligonucleotides spanning the -1651 SNP; APEX1 did not associate with scrambled control oligonucleotides. This assay indicated that APEX1 is bound to both the -1651C oligonucleotide and -1651 T oligonucleotides. However, the T allele gave a consistently stronger signal ( Figure 1D) .
Finally, the association of APEX1 with the promoter region of CYP11B2 was confirmed using a chromatin immunoprecipitation (ChIP) assay. Cross-linked, sheared chromatin preparations from H295R cells were immunoprecipitated by the APEX1 antibody. The precipitated DNA was then quantified by real-time PCR amplification of the CYP11B2 promoter region, which showed a 102Ϯ5-fold increase over control DNA. This confirmed APEX1 association with the endogenous promoter of CYP11B2 in an in vitro model of human steroidogenesis.
Confirmation that APEX1 Is a Transcriptional Repressor of Human CYP11B2
In order to investigate the precise impact of APEX1 on transcription, the effect of E3330, a small molecule inhibitor of APEX1, was assessed using the reporter plasmids described above. Under basal conditions, the addition of E3330 tended to increase the transcriptional activity of both plasmids, but this failed to achieve statistical significance ( Figure  2A ). However, following stimulation with angiotensin II (1ϫ10 Ϫ7 M), the -1651T plasmid demonstrated increased transcriptional activity in the presence of APEX1 inhibitor, relative to its control, an effect that was not seen with the -1651C plasmid ( Figure 2B) .
The role of APEX1 as a transcriptional repressor was further confirmed using siRNA knockdown of APEX1, verified by Western blotting ( Figure 2C ); this resulted in significantly increased luciferase gene expression by both constructs. In addition, overexpression of APEX1 by cotransfection of an APEX1 expression vector ( Figure 2D ) demonstrated the expected decrease in transcriptional activity of the reporter plasmids.
In summary, these data are consistent with the hypothesis that APEX1 functions as a negative regulator of CYP11B2 transcription. Inhibition of this protein therefore leads to up regulation of CYP11B2 transcription, and overexpression is associated with reduced transcriptional activity. Consistent with the data presented in Figure 1D , where APEX1 is seen to bind to oligonucleotides containing both the C and T allele (albeit with to a greater degree in the T allele), there is a clear effect of manipulating APEX1 in both the -1651T and -1651 C reporters constructs.
Functional Effect of the -1651 SNP In Vivo
The relationship between aldosterone secretion and the -1651 SNP (in combination with other, linked SNPs in the CYP11B2 5Ј regulatory region) was investigated in 60 normal subjects. Demographic data for study participants are shown in Table 2 . Individuals adhered to a standardized salt diet, which was designed to provide 100 mmol sodium per 24 hours, for a 3-day period. On the final day, 24-hour urine samples were collected, and subjects with urinary sodium excretion Ͼ150 mmol per 24 hours were excluded from further analysis. Urinary sodium excretion of participants homozygous for either the -1651T or -1651C allele was compared, and no significant difference was observed between these groups. Urinary aldosterone metabolites were measured and mean tetrahydroaldosterone (THAldo) for participants homozygous for the T allele at -1651 SNP (TT subjects, 36.10Ϯ20.04 g per 24 hours), heterozygous for -1651 SNP (TC subjects, 48.98Ϯ24.30 g per 24 hours), and homozygous for the C allele at Ϫ1651 SNP (CC subjects, 57.14Ϯ24.00 g per 24 hours) are shown in Figure 3 , with THAldo found to be significantly lower in the TT group than the CC group. Despite the trend for increased THAldo (TTϽTCϽTT), analysis by analysis of variance (ANOVA) was not statistically significant.
Discussion
The CYP11B2 gene is a logical candidate that might plausibly contribute to the phenotype of hypertension and relative aldosterone excess, given that its enzyme product, aldosterone synthase, regulates an important rate-limiting step in aldosterone production. The C/T SNP at -344 of CYP11B2 has been extensively investigated; although there is considerable heterogeneity among different ethnic groups, a meta-analysis indicated that individuals homozygous for -344C have a 17% lower risk of hypertension than do individuals homozygous for -344T. 9 However, deletion of this site showed no significant effect on in vitro gene transcription, and the mechanism underlying its association with hypertension remains obscure. We hypothesized that the -344 SNP acts as a marker for a causal variant elsewhere in the 5Ј regulatory region of CYP11B2. We have shown that the -1651 SNP is in strong LD with the -344 SNP in a Caucasian population and present data supporting its functional impact on CYP11B2 transcription through altered binding affinity of the novel transcriptional regulator, APEX1. We have also shown that the -1651 SNP is associated with altered excretion of the principal metabolite of aldosterone (THAldo) in vivo with subjects homozygous for -1651C having higher levels of THAldo than their homozygous -1651T counterparts. Urinary THAldo Demographic data for participants homozygous for the T allele at -1651 SNP (-1651 TT), heterozygous for -1651 SNP (-1651 TC) and homozygous for the C allele at Ϫ1651 SNP (-1651 CC). Data are presented as meanϮSD, with statistical analysis by †analysis of variance or ‡ 2 .
NS indicates not significant. excretion has the advantage over plasma concentrations of aldosterone in being an integration of aldosterone production over a 24-hour period. As such, it is not subject to the degree of variation that is observed in plasma measurements, even under carefully controlled conditions as in these studies, (posture, sodium intake, time of day, etc). Thus, this provided strong evidence that the polymorphism at -1651 associated with an intermediate phenotype. These in vivo data are consistent with the in vitro findings: -1651C reporter gene constructs have a higher level of expression than do -1651T constructs. Importantly, these data are also internally consistent with earlier studies; -1651C, which binds APEX1 with reduced affinity and is associated with higher aldosterone metabolite excretion, is in very tight LD with the -344T variant previously associated with increased aldosterone levels and greater risk of hypertension. 10 In view of the finding that altered reporter gene expression is determined by a single polymorphic variant at -1651, we carried out a series of studies to understand the putative mechanism. Previous investigations have contributed significantly to our understanding of CYP11B2 transcriptional regulation, 13,19 -21 but few have examined further than 1.5 kilobases upstream of the transcription start site. We demonstrated differential binding of adrenal nuclear proteins to the -1651T and -1651C alleles. Rather than attempt to identify the protein from a list of likely candidates using supershift assays, we used an experimental approach, free of a priori assumptions. Using pull-down assay and proteomic analysis, we showed that differential binding at -1651 was probably due to the transcriptional repressor APEX1 and not, as suggested by initial bioinformatic screens, by NR5A1 (SF-1). This association was confirmed by directly probing an oligonucleotide: protein complex for APEX1. In addition, ChIP assays demonstrated APEX1 binding to a DNA sequence that encompasses the -1651 SNP of human CYP11B2. This is a novel finding, as APEX1 has not previously been associated with the regulation of steroidogenic genes. The role of APEX1 as a transcriptional repressor was confirmed by its inhibition using a small molecule inhibitor and by its siRNA knockdown, both of which increased reporter gene expression. In contrast, overexpression of APEX1 by cotransfection of an APEX1 expression vector was clearly associated with reduced transcriptional activity. Both the reporter construct containing the T allele and the reporter construct containing the C allele demonstrate altered transcriptional activity on manipulation of APEX1 expression. We believe that this is not an unexpected result, as the pull-down assay demonstrated binding of APEX1 to both allelic fragments. We suggest that, in the context of a major over-or underexpression of APEX1, differential effects due to altered affinity of binding will be hard to demonstrate. Nevertheless, these data-along with the clear demonstration of binding of APEX1 to the regulatory region of CYP11B2 that incorporates -1651 in EMSA and CHIP experiments, and evidence of a differential effect on reporter function in the pharmacological inhibition and the knock-down assays-offer a clear, plausible means by which alteration of a single base in the CYP11B2 promoter could disrupt transcriptional regulation via differential binding of a repressive transcription factor. APEX1 (apurinic/apyrimidinic endonuclease, also known as APE 1, Ref-1, or HAP-1) is encoded on chromosome 14 and is ubiquitously expressed. It was first described as a key enzyme in the base excision repair (BER) pathway, 22 where its role is to cut the phosophodiester backbone of DNA immediately 5Ј to an abasic site, usually formed through the removal of bulky base damage by the action of a DNA glycosylase. APEX1 has wider functions, including a role as a redox coactivator in mammals. 23 Several transcription factors possess a redox-sensitive cysteine residue that can be reduced by APEX1, thereby enhancing DNA-binding activity. For example, members of the CREB/ATF and AP1 family can be reduced by APEX1. 23, 24 These transcription factors have been implicated in the regulation of CYP11B2 21 and have been shown to bind to the CRE element in the CYP11B2 promoter, 25 increasing transcription of aldosterone synthase. Thus, it may be that the APEX1 effect on transcriptional regulation of CYP11B2 is mediated via a redox interaction with activating transcription factors. Most interactions between APEX1 and transcription factors described to date suggest that APEX1 is a positive regulator of expression, converting transcription factors from an oxidized to a reduced state, which allows them to bind target promoters and activate gene transcription, 26 rather than inhibit it. While it is possible that the binding of APEX1 at -1651 prevents it from participating in redox reactions with CREB/ATF-1 transcription factors, thus reducing transcription, further evidence would be required to confirm this. Interaction between these transcription factors and APEX1 may also explain why transcriptional activity is altered in both the -1651C and -1651T reporter constructs in the context of substantial up-or down-regulated APEX1 expression, as shown in the above experiments.
Alternatively, APEX1 may use a mechanism similar to that by which it regulates the parathyroid hormone (PTH) gene, 27 and its own expression. 28 In these circumstances, APEX1 apparently acts as a repressive transcription factor by binding to the negative calcium response elements (nCaRE) in these genes' promoters, either as a homo-or heterodimer. Indeed, the sequences of previously reported nCaRE sites are markedly similar to those immediately surrounding the -1651 SNP (Online Figure II) . It is interesting to note that members of the RNPK family have been shown to heterodimerise with APEX1. 28 Although hnRNPK was also identified in a DNAprotein complex, further confirmation would be required to clarify whether it is also involved in the regulation of CYP11B2.
Finally, it is relevant that, although homozygous APEX1-null mice die in utero, 29 heterozygous animals with a single active gene survive to adulthood and are reported to be hypertensive 30 ; to date, there has been no exploration of the renin/angiotensin/aldosterone system in this model, and the blood pressure phenotype is said to be mediated, at least in part, by reduced endothelial nitric oxide production and increased vascular tone, features that are also present in experimental models and clinical syndromes of aldosterone excess. 31, 32 It is also pertinent to note that a case/control study examining the association of polymorphisms in the human APEX1 gene with hypertension has suggested that it may confer susceptibility to high blood pressure. 33 These data contribute to a body of evidence that suggests the role of APEX1 in hypertension is deserving of further analysis.
In summary, we have shown that APEX1 is a novel repressor of CYP11B2 transcription. Furthermore, alterations in CYP11B2 expression that associate with the -1651 SNP may be attributable to differential APEX1 binding due to the disruption of a predicted binding site at this position. In vivo, we demonstrated that the allele predicted to bind APEX1 with greater affinity associates with reduced excretion of aldosterone metabolites, and this is consistent with a transcriptionally repressive role of APEX1. APEX1 is a key enzyme in DNA repair and as such has been the focus of investigations examining the molecular mechanisms of a variety of malignant conditions. Clearly, this would be a major hurdle to the progress of targeting APEX1 in the future as a possible strategy for managing blood pressure. Nevertheless, a greater understanding of the mechanism by which APEX1 regulates CYP11B2 expression would be enlightening and may lead to novel therapeutic approaches.
